Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions

eJHaem

article

Ajay Major¹  Edward R. Scheffer Cliff²  Daniel A. Ermann⁴  Urshila Durani⁵  David A. Russler-Germain⁶ 

[1] Section of Hematology/Oncology, Department of Medicine, University of Chicago;Department of Health Policy and Management, Harvard T.H. Chan School of Public Health;Program on Regulation, Therapeutics and Law, Brigham and Women's Hospital, Harvard Medical School;Department of Hematology/Oncology, Huntsman Cancer Institute, University of Utah;Division of Hematology, Department of Medicine, Mayo Clinic;Division of Oncology, Department of Medicine, Washington University School of Medicine

关键词: chemotherapy;    clinical trials;    lymphomas;   

DOI  :  10.1002/jha2.505

来源: Wiley

【 摘 要 】

In the POLARIX trial, pola-R-CHP demonstrated improved progression-free survival (PFS) compared to R-CHOP in untreated intermediate- to high-risk DLBCL. We surveyed practicing clinicians regarding their interpretation of POLARIX, including impressions of efficacy, safety, and cost. Of 174 respondents, most from academic centers (82%) in the United States (57%), 70% stated they would not replace R-CHOP with pola-R-CHP due to insufficient PFS difference, lack of overall survival benefit, and excessive cost. Respondents not recommending pola-R-CHP expressed concerns about financial implications for both society and patients. We observed considerable heterogeneity in both study interpretation and plans for real-world implementation of pola-R-CHP.

【 授权许可】

Unknown